Johnson & Johnson price target raised to $175 from $170 at Credit Suisse

Credit Suisse analyst Trung Huynh raised the firm’s price target on Johnson & Johnson to $175 from $170 and keeps a Neutral rating on the shares. Johnson & Johnson’s Q2 was “impressive,” including strong performances from the Pharma business, robust oncology performance, and MedTech growth, the analyst tells investors in a research note. If the company can continue this momentum to execute on the base-business and headwinds for Med Devices are tempered, J&J’s guidance may be conservative, the firm contends.